New radiopharmaceutical clues to the ‘master switch’ protein responsible for cancer growth

0
42


Clinical evaluation of [18F]DASA-23. A. Maximum full-body PET intensity projection images at different time points afterwards [18F]Administration of DASA-23 in a healthy volunteer. B. Axial representative [18F]PET DASA-23 images of a healthy human brain at various times added together after tracer administration. C. Representative summary 30-60 minutes [18F]PET images DASA-23 in patients with intracranial malignancies. Standardized absorption values ​​(SUV) and tumor-brain values ​​(TBR) are shown. Credit: C Beinat et. at, Stanford University, Stanford, CA.

A protein that is critical in the metabolism of cancer cells has been first imagined with a newly developed radiopharmaceutical, 18F-DASA-23. Imaging with this new agent may improve the assessment of response to treatment for patients, specifically those with brain tumors. This study was presented at the 2021 annual meeting of the Society of Nuclear Medicine and Molecular Imaging.

Tumor cells undergo various changes to survive and thrive in the body. One of the key changes they make is to modify a master switch, known as pyruvate kinase M2 (PKM2). PKM2 controls cell metabolism and allows the cell to make the most of it necessary for cell division.

“Until now we had no way to assess the presence or activity levels of the PKM2 protein involved in this switch,” said Corinne Beinat, PhD, radiology instructor at Stanford University’s radiology / molecular imaging program at Stanford. , California. “Through the development of 18F-DASA-23, this is the first time we can non-invasively interrogate the biochemistry of a tumor with respect to this PKM2. “

The study focused on patients with glioblastoma , as normal brain cells have very low levels of PKM2. Healthy volunteers and glioblastoma patients underwent positron emission / MRI tomography with 18F-DASA-23. The radiopharmaceutical was successful in visualizing PKM2 in patients with glioblastoma, while it was rapidly removed from the bodies of .

“This radiopharmaceutical can be very beneficial in assessing whether treatments with brain tumors work,” Beinat said. “For example, if a brain tumor is treated with a drug and an image is taken with 18F-DASA-23, we can know very quickly if the therapeutic approach works. If it is not effective, we will not have to waste any more time waiting to see if the tumor itself is shrinking “.

He added that 18F-DASA-23 could also be used in other cancers or to learn more about how normal tissues adjust their metabolism during development or in response to various environmental conditions.


Researchers analyze brain tumors and response to therapy with a new metabolic PET tracer


More information:
Abstract 99. “Initial clinical evaluation of [18F]DASA-23, a PET imager for the evaluation of pyruvate kinase M2 aberrantly expressed in glioblastoma, “Corinne Beinat, Chirag Patel, Tom Haywood, Lewis Naya, Jessa Castillo, Bin Shen, Tarik Massoud, Andrei Iagaru, Guido Davidzon, Lawrence Recht and Sanjiv Gambhir, Stanford University, Stanford, California.

Provided by the Society of Nuclear Medicine and Molecular Imaging

Citation: New Radiopharmaceutical Tracks of “Master Switch” Protein Responsible for Cancer Growth (2021, June 15) Retrieved June 15, 2021 at https://medicalxpress.com/news/2021-06-radiopharmaceutical-tracks-master- protein-responsible.html

This document is subject to copyright. Apart from any fair treatment for private study or research purposes, no part may be reproduced without written permission. Content is provided for informational purposes only.





Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here